Financial Performance - The company's operating revenue for Q1 2023 was CNY 350,378,358.40, representing an increase of 11.13% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 60,246,349.21, reflecting a significant increase of 54.82% year-on-year[5]. - Basic earnings per share were CNY 0.14, which is a 55.56% increase from the same period last year[5]. - The total comprehensive income for Q1 2023 was CNY 61,688,708.37, compared to CNY 43,005,260.12 in Q1 2022, reflecting an increase of 43.4%[18]. - The net profit attributable to the parent company for Q1 2023 was CNY 60,246,349.21, an increase from CNY 38,912,971.65 in Q1 2022, representing a growth of 54.5%[18]. Cash Flow - The net cash flow from operating activities reached CNY 50,520,885.53, marking a substantial increase of 91.09% compared to the previous year[5]. - Cash inflows from operating activities for Q1 2023 totaled CNY 372,965,931.43, compared to CNY 298,546,465.92 in Q1 2022, marking an increase of 24.9%[19]. - The net cash flow from operating activities for Q1 2023 was CNY 50,520,885.53, up from CNY 26,438,423.95 in Q1 2022, representing a growth of 91.0%[19]. - Cash inflows from investment activities in Q1 2023 were CNY 638,457,387.79, compared to CNY 433,068,142.09 in Q1 2022, an increase of 47.5%[20]. - The company reported a total cash outflow from financing activities of CNY 957,506.60 in Q1 2023, compared to CNY 2,575,262.17 in Q1 2022, indicating a decrease of 62.8%[20]. Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 1,732,917,426.72, up 4.10% from the end of the previous year[6]. - The total liabilities as of March 31, 2023, were ¥446,568,986.01, slightly up from ¥444,132,719.59 at the end of 2022[14]. - The company's cash and cash equivalents decreased to ¥378,031,020.37 from ¥519,321,896.55 at the end of 2022, a decline of 27.2%[12]. - The total non-current liabilities amounted to approximately $32.3 million, slightly down from $33.0 million[25]. - Current liabilities reached approximately $411.8 million, with accounts payable constituting $236.9 million[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,226[9]. - The largest shareholder, Tibet Weixin Kang Investment Management Co., Ltd., held 47.17% of the shares, amounting to 205,248,960 shares[9]. - Shareholders' equity attributable to the parent company was CNY 1,286,348,440.71, an increase of 5.39% compared to the previous year[6]. - Shareholders' equity stood at approximately $1.221 billion, with retained earnings of approximately $392.9 million[25]. Research and Development - Research and development expenses in Q1 2023 amounted to ¥17,089,273.70, compared to ¥11,045,443.22 in Q1 2022, indicating a growth of 54.7%[17]. - The company reported a total of $38.1 million in development expenditures, consistent with the previous period[24]. Accounting Changes - The company implemented new accounting standards starting in 2023, affecting the initial recognition of deferred tax assets and liabilities[21].

Financial Performance - The company's operating revenue for 2022 was CNY 1,398,543,027.72, representing a year-on-year increase of 35.31% compared to CNY 1,033,622,524.77 in 2021[22]. - The net profit attributable to shareholders of the listed company reached CNY 176,958,679.06, an increase of 84.50% from CNY 95,911,098.26 in the previous year[22]. - The net cash flow from operating activities was CNY 246,153,584.39, reflecting a 44.21% increase compared to CNY 170,688,769.46 in 2021[23]. - The total assets of the company at the end of 2022 were CNY 1,664,718,174.54, which is an 11.31% increase from CNY 1,495,569,265.97 at the end of 2021[23]. - The net assets attributable to shareholders of the listed company increased to CNY 1,220,585,454.95, a growth of 14.37% from CNY 1,067,264,112.89 in the previous year[23]. - The company's operating revenue for 2022 reached RMB 1.399 billion, representing a year-on-year increase of 35.31%[32]. - Net profit attributable to shareholders increased by 84.50% year-on-year, amounting to RMB 177 million, while the net profit excluding non-recurring gains and losses rose by 90.95% to RMB 155 million[25][32]. - Basic and diluted earnings per share increased by 78.26% to RMB 0.41, and the basic earnings per share after excluding non-recurring gains and losses rose by 89.47% to RMB 0.36[24][25]. - The weighted average return on equity increased by 6.11 percentage points to 15.55%[24]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.35 per 10 shares to all shareholders, pending approval at the shareholders' meeting[5]. - The company declared a cash dividend of CNY 102,262,952.50, which represents 57.79% of the net profit attributable to ordinary shareholders in the consolidated financial statements[158]. - The cash dividend per 10 shares is CNY 2.35, with no stock bonus or capital increase from capital reserves[158]. - The company distributed cash dividends of 1.6 yuan per 10 shares, totaling 69,747,040 yuan (including tax) based on a total share capital of 435,919,000 shares[155]. Market and Sales Performance - The sales revenue of the multi-vitamin injection product reached RMB 182 million, a significant increase of 232.17%[33]. - The market terminal sales of trace element injection reached 866 million CNY, a year-on-year increase of 14.62%, with a market share of 15.48% in public medical institutions[34]. - The pediatric multivitamin injection achieved sales revenue of 45 million CNY in 2022, representing a year-on-year growth of 52.97%[34]. - The company has completed bidding and listing in 30 provincial administrative regions for its multi-vitamin injection, maintaining over 80% market share in similar products[33]. - The company has strengthened its sales channel construction and academic promotion efforts to support sales growth[33]. - The self-produced sales model generated ¥406,404,654.86 in revenue, with a gross margin of 91.29%[70]. - The cooperative sales model contributed ¥991,909,015.06, with a gross margin of 36.77%[70]. Research and Development - The company has over 30 ongoing research projects, with three products expected to receive approval in 2023[36]. - The company is actively enhancing its R&D capabilities, focusing on high-difficulty and high-barrier products, and has initiated the construction of a new laboratory in Nanjing[35]. - The company has received acceptance for the registration applications of five products, including dopamine hydrochloride injection and various trace element injections[36]. - The company emphasizes quality management and lean production principles, ensuring strict control over all stages from R&D to logistics[37]. - The company is committed to R&D innovation, continuously developing new products with independent intellectual property rights in the fields of vitamins and trace elements[46]. - The company has developed over 30 new product projects, with 14 invention patents and 17 new drug certificates obtained since 2015[62]. - Research and development expenses increased by 90.57% to 72.45 million RMB, indicating a strong focus on innovation[67]. - The company's R&D investment accounted for 5.71% of its operating revenue and 6.55% of its net assets during the reporting period[101]. - The company’s R&D investment is crucial for maintaining its innovative product pipeline and market competitiveness[96]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors with expertise in accounting, law, and pharmaceuticals, ensuring compliance with legal requirements[126]. - The company has established a modern corporate governance structure that promotes effective operation and protects the interests of all shareholders[125]. - The company maintains a transparent information disclosure system, ensuring all shareholders have equal access to information[128]. - The company has implemented a performance evaluation and incentive mechanism to motivate senior management and employees based on annual performance assessments[127]. - The company has established a compensation and assessment committee to ensure competitive and balanced remuneration[138]. Environmental Responsibility - The company has not experienced any environmental pollution incidents during the reporting period and has not faced any administrative penalties related to environmental protection[180]. - The company has implemented a detailed environmental management system and performance assessment criteria, integrating environmental management into daily operations[180]. - The company has committed to reducing carbon emissions but did not disclose specific measures or results during the reporting period[181]. - The company has focused on optimizing production processes and enhancing material recycling to minimize waste and emissions[180]. - The company has conducted regular fire safety inspections to eliminate fire hazards and ensure the normal operation of fire safety facilities[180]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[7]. - The company acknowledges potential risks from policy changes in the pharmaceutical industry, which may impact operational models and strategies[120]. - The company faces market risks related to drug price adjustments due to regulatory controls, which may negatively impact profitability over the long term[122]. - The company has a significant number of products in development, with a focus on establishing effective risk assessment and prevention mechanisms in its R&D processes[123]. Strategic Initiatives - The company is committed to innovation-driven strategies, optimizing product layout and structure, and enhancing R&D talent retention[35]. - The company is actively seeking international market opportunities for its core products to drive growth[118]. - The company plans to expand its research and development capabilities with the construction of the Jiangsu Zhongwei Kang R&D Center[86]. - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[133].

会议召开地点：上海证券交易所上证路演中心（网址：http://roadsho w.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 5 月 4 日(星期四) 至 5 月 10 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过西藏卫信康医药股份有 限公司（以下简称"公司"）邮箱 wxk@wxkpharma.com 进行提问。公司将在信息 披露允许的范围内，在说明会上对投资者普遍关注的问题进行回答。 公司已于 2023 年 4 月 26 日发布公司 2022 年年度报告、2023 年第一季度报 告，为便于广大投资者更全面深入地了解公司 2022 年度、2023 年第一季度经营 成果、财务状况，公司计划于 2023 年 5 月 11 日 15:00-16:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 证券代码：603676 证券简称：卫信康 公告编号：2023-020 西藏卫信康医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|---------------------------------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | 编号： 2022-011 | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | ■路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 人员 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------| | | | | 编号： 2022-010 | | | | | | | | □特定对象调研 □分析师会议 | | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2022-012 | --- | --- | --- | --- | --- | |----------------|----------------------------------------------------------|----------------------------------|-------|--------------------| | | | | | | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | ■其他：电话会议 | | | | | 参与单位名称及 | 东吴证券、太平资管 | | | | | 人员姓名 | 华西证券、农银汇理基金 2022 年 05 月 17 日， | 15:00-16:00 | | | | 时间 | 年 月 日， | | | | | 地点 | 2022 05 18 | 10:00-11:1 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|---------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | | | | 编号： 2022-017 | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 | 华西证券：王帅、王雨珩 | | | | 人员姓名 | 新华基金：赵东宇、李娜 | | | | 时间 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------|------------------------------------| | | | | 编号： 2022-016 | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | | 类别 | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 | 中泰证券：李霁阳 | | | | 人员姓名 | 国泰基金：申坤、亿林、叶烽、张慧芝 | | | | 时间 | 2022 年 6 月 23 日 | 1 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------|------------------------| | | | | 编号： | 2022-018 | | | | | | | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | ■其他：电话会议 | | | | | 参与单位名称及 人员姓名 | 民生证券：许睿、孙怡 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2022-014 | --- | --- | --- | --- | |----------------|--------------------------------------|------------------------------------------------------|-------| | | | | | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | | 2022 年 06 月 02 日 | | | | | | 东吴证券：秦凯、宋金洋、周新明、黄海珠、朱国广 | | | | 宝盈基金：刘迪、姚艺、朱建明 | | | | | 中信保诚：陈爽、杨强 | | | | | | 华夏基金：胥梦缘、周天翎、孙明达、陈斌 | | | | 建信基金：马牧青、郑丁源 | | | | | 信达澳银：李 ...